GSK opens first-in-Singapore high potency manufacturing and testing facility for next generation cancer treatments
21 November 2022 | Monday | News
- S$44m investment in the new high potency manufacturing facility and laboratory further strengthens Jurong site capabilities to launch new products more quickly
- Facility will manufacture a key ingredient for antibody drug conjugates (ADCs)
“GSK’s new facility in Jurong is a positive step as we continue to spearhead innovation in our supply chain to impact health and lives in Singapore and worldwide. With new capabilities to handle high-potency components effectively, we are in a good position to explore new frontiers in oncology and embark on a new era of manufacturing and delivering breakthrough cancer treatments.”
Regis Simard
President, Global Supply Chain
GSK
“The opening of GSK’s new facility demonstrates how global healthcare companies can tap on Singapore’s world-class infrastructure and talent to deliver innovative new products. We look forward to deepening our long-standing partnership with GSK, as we work together to transform the biopharmaceutical manufacturing sector and create good jobs for Singaporeans.”
Jacqueline Poh
Managing Director
EDB
“JTC’s ability to facilitate GSK’s expansion today is a testament to Singapore’s advanced industrial planning and infrastructure readiness to support business growth. GSK’s new facility exemplifies our vision to anchor strong ecosystems in our industrial spaces.”
Tan Boon Khai
Chief Executive Officer
JTC
This facility is the first in Singapore capable of producing highly potent cytotoxic ingredients in ADCs, for breakthrough immunotherapy cancer treatments. It is equipped with advanced features such as specialised equipment, automated operations, exceptional containment capabilities and strict cross-contamination control. It is built to facilitate complete in-house manufacturing to safeguard supply chain processes, quality control and timeliness of delivery. It also features leadingedge capabilities to handle high potency manufacturing under a highly safe and controlled environment.
With the addition of the HPF, GSK has further strengthened the Jurong site capabilities as a New Product Introduction (NPI) site to launch new products more quickly. The capability to produce high potency components at scale helps to meet the increasing demand for oncology treatments around the world.
Most Read
- Lack of Regular Screening Fuels Rise in Late-Stage Breast Cancer in Hong Kong, New Report Reveals
- BIOCHINA 2025: Connecting Global Innovators with China's Leading Biotech Firms
- Leon Wyszkowski, President of Analytical Services, Discusses Thermo Fisher's Strategic Move: Expanding Bioanalytical Capabilities in Europe with New Sweden Lab
- The Role of Policy and Public Health Initiatives in Addressing Women's Cancer Care in Asia
- Redefining Patient Safety in the Age of Healthtech
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
Editor Picks
